Liver Failure Clinical Trial
Official title:
Low Dose Vasopressin for Renal Protection During Liver Transplantation
Verified date | August 2018 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.
Status | Completed |
Enrollment | 18 |
Est. completion date | August 2011 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - > 18 years of age - undergoing liver transplant - ability to provide informed consent. If patient is unable to give informed consent i.e. hepatic encephalopathy, consent may be obtained from the patient's legally authorized representative Exclusion Criteria: - < 18 years of age - renal failure |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | Emory University |
United States,
Csete M. IARS 2007 Review Course Lectures: Anesthesia for Liver Transplantation. Anes Analg 2007; 104:19-24,2007.
De Wolf AM. Preoperative optimization of patients with liver disease. Curr Opin Anaesthesiol. 2005 Jun;18(3):325-31. — View Citation
Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8. — View Citation
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002 Apr;122(4):923-30. — View Citation
Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006 Mar;43(3):385-94. Review. — View Citation
Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001 Jan-Mar;64(1):15-9. — View Citation
Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002 Oct;36(4 Pt 1):941-8. — View Citation
Roth JV. The use of vasopressin bolus to treat refractory hypotension secondary to reperfusion during orthotopic liver transplantation. Anesth Analg. 2006 Jul;103(1):261. — View Citation
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003 Feb;18(2):152-6. — View Citation
Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000 Jul;33(1):43-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Creatinine Levels | baseline to 48 hours postop | ||
Primary | Change in Urine Output | 24 hours to 48 hours postop | ||
Secondary | Count of Participants Who Needed Diuretics Postoperatively | 48 hours | ||
Secondary | Count of Patient Who Need Vasopressers in the Perioperative Period | 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03791190 -
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
|
N/A | |
Recruiting |
NCT05989958 -
The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
|
Phase 1 | |
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Recruiting |
NCT01698723 -
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
|
Phase 2 | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT01404793 -
SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation
|
N/A | |
Completed |
NCT03864497 -
Myocardial Perfusion Imaging in Liver Transplantation Candidates
|
||
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Completed |
NCT03650920 -
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
|
N/A | |
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05726032 -
Empagliflozin in Patients With Cirrhosis and Ascites
|
Phase 2 | |
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Not yet recruiting |
NCT01961440 -
Prognosis Scoring System for Acute-on-Chronic Liver Failure
|
N/A | |
Active, not recruiting |
NCT01221454 -
Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure
|
Phase 2 | |
Completed |
NCT00772148 -
Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
|
Phase 2 | |
Completed |
NCT05592106 -
Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
|
||
Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|
||
Recruiting |
NCT04221672 -
The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
|
Phase 3 |